[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638236":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":20,"studyPopulation":13,"armGroups":21,"interventions":28,"overallOfficials":13,"centralContacts":33,"locations":13,"responsibleParty":39,"collaborators":41,"id":45,"slug":13,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":13,"enrollmentInfo":53,"targetDuration":13,"studyType":56,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":67,"whyStopped":13,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":13},{"fullName":5,"class":6},"ANRS, Emerging Infectious Diseases","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"The main outcomes are: the presence of neutralizing antibodies in the serum and the presence of detectable mpox virus-specific memory B cells.","Neutralizing antibodies titers will be measured with a semi-automated cell-based assay using live mpox virus. Memory B cells will be measured by flow cytometry and other techniques.","Baseline (Day 1)",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","HEALTH_SERVICES_RESEARCH",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE","Single inclusion visit with data collection and blood sample. No further follow-up of participants.\n\nA total of 60 participants previously enrolled in the main cohort ANRS 0758s MOSAIC are planned to be included, distributed among France (n = 35), Italy (n = 20), and Switzerland (n = 5).",[22],{"label":23,"type":24,"description":25,"interventionNames":26},"study population","EXPERIMENTAL","Procedure: Patients included in the ANRS0758s MOSAIC cohort will be recalled \\>3 years after their infection to come to hospital to have a review of medical history since mpox infection, a clinical examination in case of symptoms suggestive of a mpox infection and samples taken for the study.",[27],"Procedure: blood sampling",[29],{"type":30,"name":31,"description":25,"armGroupLabels":32,"otherNames":13},"PROCEDURE","blood sampling",[23],[34],{"name":35,"role":36,"phone":37,"phoneExt":13,"email":38},"Aida TAIEB","CONTACT","+33 (0)1 82 53 35 66","aida.taieb@inserm.fr",{"type":40,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR",[42],{"name":43,"class":44},"Assistance Publique - Hôpitaux de Paris","OTHER","100638236",false,"NCT07592429","Assessment of Immune Memory - Humoral and Cellular - in mPOX-infected Patients : an Ancillary Study of the ANRS0258s MOSAIC Cohort","POXAIM","Inclusion Criteria:\n\n* Written informed consent, signed by the participant and the investigator prior to any study-related procedure\n* Person previously enrolled in the ANR0258s-MOSAIC cohort (see Appendix 19.2 for MOSAIC inclusion criteria) between July 2022 and July 2023\n* Person with a blood sample taken within 8 months following mpox infection\n* ≥ 18 years old\n\nExclusion Criteria:\n\n* Individuals who, in the investigator's opinion, are unlikely to comply with study procedures or whose medical condition is incompatible with study participation\n* For France only: person not affiliated to or not benefiting from a social security scheme in accordance with article L1121-11 of the French Public Health Code (Aide Médicale d'Etat \\[AME\\] does not constitute a social security scheme)\n* Pregnant or breastfeeding women\n* Individuals under guardianship or curatorship, or deprived of liberty by judicial or administrative decision","ALL","18 Years",{"count":54,"type":55},60,"ESTIMATED","INTERVENTIONAL",[15],"Primary objective The overall objective is to assess the long-term amplitude and durability of the immune responses after mpox virus (MPXV) infection.\n\nPrimary endpoint The main outcomes are: the presence of neutralizing antibodies in the serum and the presence of detectable mpox virus-specific memory B cells. Neutralizing antibodies titers will be measured with a semi-automated cell-based assay using live mpox virus. Memory B cells will be measured by flow cytometry and other techniques.\n\nSecondary objectives\n\n1. Assess the amplitude and the stability of the MPXV antigen-specific B-cell memory response after infection, against the immunodominant antigens A27, A33, B5, L1, D8, and H3.\n2. Assess the breadth of the B-cell repertoire and its neutralizing capacity in a subset of patients\n3. Assess the humoral immunity using different serological techniques, for the detection and quantification of anti-MPXV antibodies, and assess the seroneutralization capacities of each antibody.\n\nSecondary endpoints\n\n1. The presence of MPXV antigen-specific B-cell memory. Memory B cells will be measured by flow cytometry and other techniques.\n2. The breadth and neutralizing capacity of the B-cell repertoire in a subset of patients.\n3. The humoral immunity using serological techniques.",[60],"Mpox (Monkeypox)",[62,63,64,65,66],"mpox virus","Immune protection","Immune response","Immunity duration","Infection","NOT_YET_RECRUITING","2026-05-14",{"date":70,"type":71},"2026-05-18","ACTUAL",{"date":73,"type":55},"2026-07-01",{"date":75,"type":55},"2028-07-01",{"name":5,"class":6}]